drugset / Trial / NCT00395304
Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)
Phase 3
Completed
182 enrolled
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
Asthma is a common, serious illness among children in the United States. While a low dose of inhaled corticosteroids (ICS) may effectively control symptoms, some children may require additional medications to maintain adequate asthma control. This study compares the effectiveness of a higher dose of ICS, ICS combined with a long-acting beta-agonist (LABA) medication, and ICS combined with a leukotriene receptor antagonist (LTRA) medication at reducing the impact and severity of asthma exacerbations that occur in children with mild to moderate persistent asthma.
Timeline
- Start
- 2007-03
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone propionate | Other / unclassified | 100 ug | Inhaled |
| Subject | Fluticasone propionate | Other / unclassified | 250 ug | Inhaled |
| Subject | Montelukast | Other / unclassified | 5 mg | Inhaled |
| Subject | Montelukast | Other / unclassified | 10 mg | Inhaled |
| Subject | Salmeterol | Other / unclassified | 50 ug | Inhaled |